05Feb 2025
TIX100: A Novel Oral Therapy for T2D

TIX100: A Novel Oral Therapy for T2D

This study evaluates TIX100, an oral thioredoxin‐interacting protein (TXNIP) inhibitor, for obesity-associated glucose control in high-fat diet-fed and leptin-deficient mice. TIX100 improved glucose intolerance, hyperinsulinemia, and hyperglucagonemia while reducing adiposity by 15% in diet-induced obesity. Despite no weight loss in leptin-deficient mice, TIX100 improved glucose control, significantly lowering HbA1C by 2.3%. TIX100 preserved lean mass and mitigated islet cell dysfunction, suggesting its potential as a better-tolerated oral therapy for type 2 diabetes (T2D) without aggressive weight loss.

  • #endo-diabetology

Like

Save

Share